Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: A phase I California Cancer Consortium Trial

Anti-Cancer Drugs

Volumn 16, Issue 3, 2005, Pages 317-321

  Lara Jr , Primo N ^a,d,f   Law, Lisa Y ^a   Wright, John J ^e   Frankel, Paul ^b   Twardowski, Przemyslaw ^b   Lenz, Heinz Josef ^c   Lau, Derick H M ^a,b   Kawaguchi, Tomoya ^a   Gumerlock, Paul H ^a   Doroshow, James H ^b   Gandara, David R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trial; Dose escalation; Signal transduction

Indexed keywords

TIPIFARNIB;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; ASTHENIA; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; HEART ARRHYTHMIA; HUMAN; INFECTION; KIDNEY CARCINOMA; LETHARGY; LEUKOCYTE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; NEUTROPHIL; PANCREAS CANCER; PAROTID GLAND CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RASH; SEIZURE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; CALIFORNIA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN ISOPRENYLATION; QUINOLONES;

EID: 20044393284     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200503000-00011     Document Type: Article

References (14)

1. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61:131-137.
2. Sebti S, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000; 19:6584-6593.
3. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: targeting simply ras? Biochim Biophys Acta 1997; 1333:F51-F71.
4. End D, Skrzat S, Devine A, Angifaud P, Venet M, Sanz G, et al. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): biochemical and cellular effects in H-ras and K-ras dominant systems. Proc Am Ass Caner Res 1998; abstr 1847.
5. Skrzat S, Angibaud P, Venet M, Sanz G, Bowden C, End D. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumor activity. Proc Am Ass Caner Res 1998; abstr 2169.
6. Crul M, de Klerk GJ, Swart M, van't Veer LJ, de Jong D, Boerrigter L, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002; 20:2726-2735.
7. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97:3361-3369.
8. Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003; 21:2492-2499.
9. Johnson & Johnson. Non-Clinical Research Report EDMS-BEBE-1445358. Data on file; 1999.
10. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000; 18:927-941.
11. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ, Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991; 51: 3497-3502.
12. Kawaguchi T, Holland WS, Gumerlock PH. Methods for isolation and genetic analysis of circulating tumor DNA in patient plasma. In: Buolamwini JK, Adjei AA (editors): Methods in Molecular Medicine: Novel Anticancer Drug Protocols. Totowa, NJ: Humana Press; 2003, pp. 257-262.
13. Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev 2003; 17:123-129.
14. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101:1692-1697.